Evidence map›Paper›PMID 38757331›Full record

ArticleCurrent pharmaceutical biotechnology2025

Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin Chemosensitivity in Bladder Cancer Cells.

Xuhua Qiao, Rongbo Xue, Shijie Li, Jun Li, Chundong Ji

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuhua QiaoAffiliated Hospital of Panzhihua University, Panzhihua Hospital of Chinese and Western Combination, Urology Basic and Clinical Research Team of Affiliated Hospital of Panzhihua University, Urology Research and Innovation Platform of Panzhihua City, Panzhihua, Sichuan 617000, P.R. China.
Rongbo XueAffiliated Hospital of Panzhihua University, Panzhihua Hospital of Chinese and Western Combination, Urology Basic and Clinical Research Team of Affiliated Hospital of Panzhihua University, Urology Research and Innovation Platform of Panzhihua City, Panzhihua, Sichuan 617000, P.R. China.
Shijie LiAffiliated Hospital of Panzhihua University, Panzhihua Hospital of Chinese and Western Combination, Urology Basic and Clinical Research Team of Affiliated Hospital of Panzhihua University, Urology Research and Innovation Platform of Panzhihua City, Panzhihua, Sichuan 617000, P.R. China.
Jun LiAffiliated Hospital of Panzhihua University, Panzhihua Hospital of Chinese and Western Combination, Urology Basic and Clinical Research Team of Affiliated Hospital of Panzhihua University, Urology Research and Innovation Platform of Panzhihua City, Panzhihua, Sichuan 617000, P.R. China.
Chundong JiAffiliated Hospital of Panzhihua University, Panzhihua Hospital of Chinese and Western Combination, Urology Basic and Clinical Research Team of Affiliated Hospital of Panzhihua University, Urology Research and Innovation Platform of Panzhihua City, Panzhihua, Sichuan 617000, P.R. China.

Funding

Sichuan Medical And Health Care Promotion Institute of China KY2022QN0245
6 · The paper itself

Abstract

introductionThe aim of this study was to investigate the potential of dihydroartemisinin to augment the efficacy of cisplatin chemotherapy through the modulation of LASS2 expression.

methodsTCMSP, CTR-DB, TCGA-BLC, and other databases were used to analyze the possibility of LASS2 as the target gene of dihydroartemisinin. Cell experiments revealed the synergistic effect of DDP and DHA. Animal experiments showed that DHA inhibited the growth of DDP-treated mice. In addition, WB, real-time PCR, and immunohistochemical analysis showed that DHA enhanced LASS2 (CERS2) expression in bladder cancer cells and DDP-treated mice.

resultsLASS2 is associated with cisplatin chemosensitivity.LASS2 expression levels are different between BLC tissues and normal tissues. COX analysis showed that patients with high LASS2 expression had a higher cumulative overall survival rate than those with low LASS2 expression. The Sankey plot showed that LASS2 expression is lower in BLC tissues with more advanced stage and distant metastasis. The docking score of DHA and LASS2 reached the maximum value of -5.5259, indicating that DHA had a strong binding affinity with LASS2 targets. CCK8 assay showed that the most effective concentration ratio of DHA to DDP was 2.5 μg/ml + 10μg/ml.

conclusionThe upregulation of LASS2 (CERS2) expression in bladder cancer cells by DHA has been found to enhance cisplatin chemosensitivity.

Indexed as

Antineoplastic AgentsArtemisininsCisplatinMembrane ProteinsSphingosine N-AcyltransferaseTumor Suppressor ProteinsUrinary Bladder NeoplasmsAnimalsCell Line, TumorDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CAntineoplastic AgentsArtemisininsartenimolCERS2 protein, humanCisplatinMembrane ProteinsSphingosine N-AcyltransferaseTumor Suppressor Proteinsbladder cancerceramide synthase 2cisplatinDDP-treated mice.DihydroartemisininLASS2

Identifiers

PMID38757331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.